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2Abstract
Mutations in the progranulin (GRN) gene represent about 5-10% of frontotemporal lobar
degeneration (FTLD). We describe a proband with a novel GRN mutation c.687T>A,
p.(Tyr229*), presenting with dyspraxia, dysgraphia and dysphasia at the age of 60 and a very
severe FTLD neuropathological phenotype with TDP43 inclusions. The nephew of the
proband had signs of dementia and personality changes at the age of 60 and showed similar
but milder FTLD pathology. Three other family members had had early-onset dementia. Gene
expression studies showed decreased GRN gene expression in mutation carriers’ blood
samples. In conclusion, we describe a novel GRN, p.(Tyr229*) mutation, resulting in
haploinsufficiency of GRN and  a severe neuropathologic FTLD phenotype.
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Introduction
Frontotemporal lobar degeneration (FTLD) is the second most common cause of dementia in
patients under the age of 65 [1] and accounts for about 5-10% of all dementia patients [2,3]. It
is a group of neurodegenerative disorders, which primarily affect the frontal and temporal
cortex either symmetrically or asymmetrically. Clinically there are three disease
manifestations: behavioral variant frontotemporal dementia (bvFTD), semantic dementia (SD)
and progressive non-fluent aphasia (PNFA) the latter two presenting with symptoms affecting
primarily language. Some patients also have significant motor symptoms including
3parkinsonism. Nearly 40-50% of patients have a positive family history of dementia [4,5].
The three most common genetic causes of FTLD are mutations in the chromosome 9 open
reading frame 72 gene (C9orf72), the microtubule-associated protein tau gene (MAPT) and
the progranulin gene (GRN) [5]. GRN mutations are found in about 5-10% of all FTLD cases
worldwide [6-8] but have not been reported in the Finnish population thus far [9].
GRN gene is located on chromosome 17q21. It encodes a precursor protein that can be
cleaved to peptides called granulins [8]. Most of the known pathogenic GRN mutations are
loss-of-function mutations that cause haploinsufficiency and low plasma progranulin levels
[10,11]. There are currently almost 150 different mutations and variants reported in the GRN
gene (http://www.molgen.ua.ac.be/admutations/). GRN mutations are inherited in an
autosomal dominant pattern with incomplete penetrance. The age of onset and the clinical
presentation of mutation carriers are variable. It is believed that these are modified by other
regulatory mechanisms and risk factors such as allelic variants of the TMEM106B
(transmembrane protein 106B) gene [12,13].
GRN is a growth factor involved in multiple physiological processes. Although its exact
function in the central nervous system is still unknown it is expressed in neurons and glia cells
and is believed to have a role in several processes including inflammation, lysosomal
function, neurite outgrowth, response to stress and neuronal WNT signaling [13-15]. Of
special interest is its role as a regulator of inflammation. This immunological activity may
play a role in neurodegeneration since it was recently shown in Grn -/- mice that progranulin
deficiency leads to progressive microgial activation and increased complement production
during aging, which gradually leads to synapse pathology [16].
The neuropathology of FTLD is classified into subtypes based on the deposited abnormal
protein aggregates. Most of the cases that are tau-negative show immunoreactivity to
4ubiquitin and the majority of those have TDP-43 positive inclusions (FTLD-TDP).  FTLD-
TDP pathology is classified into four subtypes (A-D) that have different distribution types of
TDP-43 positive inclusions including neuronal intranuclear inclusions (NIIs), neuronal
cytoplasmic inclusions (NCIs), oligodendroglial inclusions and dystrophic neurites (DNs).
GRN related FTLD is associated with FTLD-TDP type A, which presents with multiple NCIs,
DNs and variable amount of NIIs. The lesions are mostly in layer 2 of the cortex [17-19].
Here we describe a family with a novel GRN mutation p.(Tyr229*). In addition to genetic
results, we present the clinical features of the diseased family members and the
neuropathological features of the index patient and her nephew.
Materials and methods
The family pedigree is shown in Figure 1. The index patient was clinically examined and
neuropsychological and imaging examinations were performed in Helsinki city hospital.
The index patient’s nephew and sister were examined in Mikkeli Central Hospital and in
HUCH Hyvinkää Hospital respectively. Neuropathological analysis was performed on the
index patient and her nephew following standard protocol.
DNA was extracted from the index patient’s liver tissue sample and her nephew’s formalin-
fixed paraffin-embedded (FFPE) spleen tissue sample with standard procedures. Participating
family members’ DNA was extracted from blood leukocytes using standard methods. Whole
exome sequencing of the index patient’s sample was performed at Institute for Molecular
Medicine Finland (FIMM).  The target enrichment was performed using Agilent SureSelect
Human All Exon V5 kit (Agilent Technologies, Santa Clara, CA, USA). The sequencing was
done on a Hiseq2500 platform (Illumina, San Diego, USA) according to manufacturer’s
protocol. Variant calling was performed using the variant calling pipeline of FIMM,
alignment was done to the human genome reference sequence hg19 (GRCh37). Clinical data
5analysis was done with OmnomicsNGS software (Euformatics, Espoo, Finland) focusing on
the genes known to cause FTLD. GenBank accession number for the reference sequence used
for GRN gene was NM_002087.3.
C9orf72 screening for a possible pathogenic hexanucleotide repeat expansion in the index
patient was performed using the repeat-primed PCR method as described by Renton et al.[20].
Sanger sequencing was performed to validate the findings of the whole exome sequencing
and to confirm segregation of the mutation with the disease in the family and to study two
known TMEM106B gene risk variants in the mutation carriers’ samples.
RNA was extracted from two mutation carriers’ blood samples with standard procedures.
mRNA was reverse-transcribed using the SensiFASTTM cDNA synthesis kit (BioLine, UK).
The GRN expression analysis was performed using commercial TaqMan gene expression
assay Hs00963707_g1 (Applied Biosystems) and the CFX96 real-time system (Bio-Rad,
Hercules, CA, USA). ß-actin (ACTB) was used as endogenous control for normalizing gene
expression quantifications. The GRN gene expression levels were expressed as 2-ΔΔCt fold
change values relative to the average of five control samples. All assays were performed using
the manufacturer’s protocol (Applied Biosystems).
Ethical approval for the study was obtained from the local ethics committee and a written
informed consent was obtained from family members and appropriate next of kin of the
deceased family members participating in the study. Participating family members received
appropriate genetic counselling.
Results
Clinical and neuropathological features
6The index patient (Individual II-1, Figure 1) was a female who presented with dyspraxia,
dysgraphia and dysphasia at the age of 60. She also had mild right sided hemiparesis and
symptoms of depression. Her head CT scan showed mild atrophy predominantly on the left
upper parietal region and posterior frontal region and a possible infarct behind the left
temporal horn.  The lateral ventricles were slightly dilated primarily on the left side. Her Mini
Mental State Examination (MMSE) score was 28/30. Single-photon emission computed
tomography (SPECT) scan at the age of 62 showed a fairly wide hypoperfusion area on the
left temporal and parietal regions especially on the anterior part of the temporal lobe. Her
symptoms progressed slowly. She had extrapyramidal symptoms and spasticity of the right
upper limb. Ultimately she became unable to speak and tetraplegic. Finally, she got
pneumonia, and passed away at the age of 78. Her clinical diagnosis was a progressive
degenerative disease, possible corticobasal degeneration.
A neuropathological examination was performed post mortem and revealed dramatic cerebral
atrophy. The weight of the brain was 782 g. Both the cerebral cortex and the white matter
were severely atrophic, as were the hippocampi, the basal ganglia and the substantia nigrae.
Microscopically, there was a dramatic neuronal loss and gliosis in the cortical areas affecting
all laminae (Fig. 2A-B) and particularly the deep layers were vacuolated. The cortical
structures appeared largely collapsed (Fig 2A), hippocampi were subtotally atrophic, and only
the neurons in the dentate fascia and CA4 were preserved. The substantia nigrae showed also
moderately severe neuronal loss without Lewy bodies. The white matter was largely atrophic
and appeared demyelinated in luxol fast blue stain (Fig 2A), and there were a large number of
concentrically hyalinized vessels particularly in the occipital lobe (Fig 2C). There were no
neurodegenerative changes in the spinal cord. The muscle sample however, revealed severe
atrophic changes, including groups of small angulate fibers, consistent with combined
neuronal and inactivity atrophy.
7Immunohistochemistry revealed numerous TDP-43- and p62-positive perinuclear inclusions
(Figure 2F) in the dentate fascia of the hippocampus. Furthermore, there was a large amount
of cytoplasmic and perinuclear TDP43-positive inclusions in all cortical areas, appearing to
be distributed throughout the collapsed cortex (Fig 2E). In addition, a large number of short
dystrophic neurites and some intranuclear “cateye”-type inclusions were found (Fig. 2E). Due
to severe atrophy, it was not possible to categorize the TDP43-pathology into any of the
established categories A-D. Abeta immunostaining showed slight positivity in some
hyalinized vessels, and a few diffuse plaques were seen. Tau and α-synuclein immunostains
were largely negative. The neuropathological diagnosis was FTLD-TDP-43. There were no
p62-positive perinuclear inclusions in the granule cells of the cerebellum. The patient’s
tetraplegia was concluded to be due to the severe cerebral atrophy and no motor neuron
disease was diagnosed.
The index patient’s nephew (Individual III-2, Figure 1) presented with symptoms of dementia
and a change in personality at the age of 60. His left hand was clumsier and slower. His head
MRI scan showed cerebral hemisphere atrophy and also hippocampal atrophy predominantly
on the right side. Neuropsychological testing revealed wide-ranging and profound dysfunction
predominantly in the frontal and right hemisphere. His clinical diagnosis was frontotemporal
dementia. His symptoms progressed quickly and he was bedridden in three years. He had
spasticity of the limbs and difficulties in swallowing. He passed away at the age of 63.
At neuropathological examination the weight of the brain was 1150g. There was considerable
cortical atrophy, most predominantly in the frontal and temporal lobes. The basal ganglia
were smaller on the right than on the left. Microscopically, neuronal loss and gliosis were
found in neocortical areas, particularly on the frontal lobes. The layer II was vacuolated (Fig
2D). There was moderate neuronal loss in the CA1 region and subiculum of the hippocampus.
8The substantia nigrae were preserved. There was only modest hyalination in the vessels of the
brain.
The immunohistochemical study showed widespread TDP-43 positive cytoplasmic and
perinucear inclusions in the cortical areas, most pronounced in the layer II.  A large number of
short dystrophic neurites were also seen, consistent with category A –type TDP43- pathology
(Fig 2E). In addition, there were some perinuclear TDP43-positive inclusions in the dentate
fascia of the hippocampus (Fig 2H). Beta-amyloid immunostain revealed a few neuritic
plaques in the hippocampal section. Tau and α-synuclein immunostains were considered
negative. The neuropathological diagnosis was FTLD-TDP-43.
The index patient’s sister (Individual II-5, Figure 1) had previously suffered from depression.
She presented with slowly progressing right lower limb weakness and clumsiness at age 68.
She also had periodical right upper limb resting tremor and progressive difficulty in finding
words and understanding speech and managing daily activities. Her MMSE score was 21/30.
Her head CT scan showed moderately strong general atrophy that was thought to be
consistent with vascular atrophy although no focal infarcts were found in the CT scan. The
scan showed signs of moderate arteriosclerosis. She was diagnosed clinically with vascular
dementia. She developed parkinsonism. She passed away at the age of 73. No
neuropathological examination was performed post mortem.
The index patient’s brother (individual II-4, Figure 1) had dementia according to family
history. He died at the age of 68, the cause of death was a cerebral infarct. The index patient’s
father (Individual I-1, Figure 1) who passed away at the age of 64 also had dementia
according to family history. His cause of death was bronchopneumonia and cerebral
arteriosclerosis. The index patient’s mother did not have dementia according to family
history. She died at the age of 74.
9Individuals III-1 and III-5 in Figure 1 have not been diagnosed with dementia at the time of
this study. They are 57 and 64 years old respectively. Individual III-1 suffers from depression
and has had difficulties managing in her job.
Genetic analyses and expression studies
Whole exome sequencing of the index patient’s sample showed a novel heterozygous
nonsense GRN mutation c.687T>A, p.(Tyr229*) (Figure 3). The mutation was confirmed by
Sanger sequencing. The mutation has not been reported in the 1000 Genomes
(http://www.1000genomes.org/) database, in the ExAC database
(http://exac.broadinstitute.org/) or in the Exome variant server database
(http://evs.gs.washington.edu/EVS/). It has not been reported in the HGMD professional
database (http://www.biobase-international.com/product/hgmd). In silico analysis with
Mutation Taster (http://www.mutationtaster.org/) predicts the mutation to be disease causing
by nonsense mediated mRNA decay.
The GRN mutation appeared to segregate with the disease in the family as it was determined
using Sanger sequencing that the index patient’s nephew (Individual III-2, Figure 1) also had
the familial mutation. There were two yet non-demented mutation carriers identified in the
family (Individuals III-1 and III-5, Figure 1). Although there was no tissue sample available
for genetic testing from individuals II-4 and II-5 (Figure 1), they were probable carriers of the
mutation, because their child (Individuals III-2 and III-5, respectively, Figure 1) and sister
(Individual II-1, Figure 1) were carriers of the familial mutation. There were no tissue
samples available for genetic testing from the index patient’s parents but as her father had
dementia according to family history it is possible that he was a carrier of the familial
mutation.
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Mutation carriers’ blood samples showed decreased mRNA expression, 45% and 48% levels
as compared to the control individuals (Figure 4) supporting the pathogenicity of the novel
mutation.
The index patient did not have a C9orf72 hexanucleotide repeat expansion mutation.
TMEM106B genotyping showed that both the index patient and her nephew (Individuals II-1
and III-2, Figure 1) were homozygous for the risk alleles rs3173615 (C/C) and rs1990622
(T/T). Of the two asymptomatic mutation carriers in Figure 1, individual III-1 was
heterozygous for the risk alleles and individual III-5 was homozygous for the protecting
alleles rs3173615 (G/G) and rs1990622 (C/C).
Discussion
We describe a novel GRN mutation in a family with dementia with an autosomal dominant
pattern of inheritance. The mutation causes a premature stop codon and is predicted to cause
loss-of-function due to nonsense mediated mRNA decay. The mutation appeared to segregate
with the disease in the family and a gene expression study showed a decrease in mRNA
expression in mutation carriers’ samples further supporting the concept of a loss-of-function
mutation.
Loss-of-function (and haploinsufficiency) resulting in reduced levels of secreted progranulin
protein has been proposed as the most common consequence of GRN mutations [10].
The neuropathological examination of two family members carrying the mutation showed
TDP-43 positive inclusions and cerebral atrophy. The index patient’s neuropathological
findings were extremely severe. The index patient’s nephew’s neuropathological phenotype
was milder and the TDP43 pathology could be classified into subtype A, in accordance with
previous reports on GRN mutation carriers. In the index patient, it was not possible to identify
the cortical layers due to nearly total loss of neurons, and it was therefore difficult to classify
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the TDP-43 pathology into any of the subtypes A-D. However, it is possible that the TDP43
pathology had represented type A at earlier stages of the disease as the TDP43 pathology
consisted of perinuclear, cytoplasmic and intranuclear inclusions in addition to a large number
of short dystrophic neurons, but at the end stage the typical predominant localization of the
changes in layer II could not be recognized. In addition to severe cortical atrophy and TDP43-
pathology, the index patient showed severe white matter atrophy and vascular hyalinization,
particularly in the occipital region, consistent with a previous MRI report on GRN mutation
carriers [21]. Interestingly, a pathological description of SVD-type arterial hyalination has
been published in FTLD-tau patients [22].
Clinically the nephew had presented with FTD that had progressed quickly compared to the
index patient who had been clinically suspected to have corticobasal syndrome and had a long
disease course. The differences between the neuropathology and clinical picture among the
family members are consistent with the previous knowledge that GRN mutations can cause
variable clinical phenotypes even within the same family. It is also known that there is
considerable variation in the age of onset (35-89 years) and in the duration of the illness (3-22
years) [23]. The duration of the illness of the index patient was 18 years, which could be an
explanation to the extremely severe neuropathological phenotype in this patient. Most
previously described neuropathologies of GRN mutation carriers have been of patients with a
much shorter duration of illness [24-26]. The variations in the phenotype even within families
have been suggested to be due to other risk factors such as variants in the TMEM106B gene
[12,13]. Interestingly in this study the index patient and her nephew were both homozygous
for the two known TMEM106B gene risk variants although their disease course was markedly
different. This suggests other factors besides the TMEM106B gene variants are responsible for
the variation in the clinical phenotype in this family.  The position of the mutation in the GRN
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gene has not been shown to have a significant effect on the phenotype, which is consistent
with the haploinsufficiency mechanism [10,24-26].
To our knowledge this is the first GRN gene mutation reported in the Finnish population. We
conclude that the novel GRN mutation c.687T>A (p.Tyr229*) is considered pathogenic by
causing nonsense mediated mRNA decay and haploinsufficiency. We recommend genetic
counselling to all mutation carriers and their family members.
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Figure 1. Family pedigree. Deceased individuals are indicated with a diagonal bar.
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Figure 2. Neuropathological features of the two neuropathologically examined patients. A
The cortical sections of the index patient showed extremely severe neuronal loss, gliosis and
vacuolation transcortically. The cortex (CTX) was thinned and atrophic as was the white
matter (WM).(occipital cortex 4X magnification, Luxol Fast Blue staining). B Higher
magnification shows that there were no or only very few neurons left in the cortex. Severe
gliosis and vacuolation was seen (haematoxylin-eosin staining, occipital cortex, 40 X
magnification). C There were many hyalinized vessels in the white matter in the index
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patient’s occipital lobe (haematoxylin-eosin staining, occipital lobe, 10X magnification). D In
the cortical sections of the index patient’s nephew, vacuolation and neuronal loss were most
pronounced in the lamina II (L2) (haematoxylin-eosin staining, frontal cortex, 10X
magnification). E In the index patient’s cortical sections, TDP43-immunostaining revealed
pathology throughout the thinned cortex, including cytoplasmic and perinuclear inclusions, a
large number of short neurites and some intranuclear inclusions (40X magnification, TDP43
immunostaining, parietal section). F . There were numerous perinuclear TDP-immunoreactive
inclusions in the hippocampal dentate fascia of the index patient (40X magnification, TDP43
immunostaining). G. There was abundant TDP-immunopositivity in the nephew’s cortical
sections, most pronounced in the lamina II (L2)  (40 X magnification, TDP43
immunostaining, frontal section). H. The perinuclear inclusions were few in number in the
dentate fascia of the nephew (40X magnification, TDP43 immunostaining).
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Figure 3. Electropherogram of the GRN mutation c.687T>A, p.(Tyr229*)
20
Figure 4. Normalized GRN mRNA expression in two carriers of the p.Tyr229* mutation
relative to the average normalized GRN mRNA expression in five unaffected controls. Fold
change was calculated with the 2-ΔΔCt method.
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